Citi initiated coverage of BioMarin (BMRN) with a Buy rating and $75 price target The firm views the stock’s “dislocated” valuation as a product of “overly cautious” views on Voxzogo’s competitive exposure. Citi sees the shares rallying over the medium term on visibility into the Amicus business.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target lowered to $62 from $64 at Leerink
- BioMarin price target lowered to $50 from $55 at H.C. Wainwright
- BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
- Morgan Stanley Sees the S&P 500 Hitting 8,300 – 2 Stocks It Says Could Surge Alongside It
- BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors